Immunic (IMUX) Competitors

Immunic (NASDAQ:IMUX) and Cartesian Therapeutics (NASDAQ:RNAC) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, valuation, analyst recommendations, profitability, media sentiment, earnings, community ranking, dividends and institutional ownership.

Which has more volatility and risk, IMUX or RNAC?

Immunic has a beta of 1.48, meaning that its stock price is 48% more volatile than the S&P 500. Comparatively, Cartesian Therapeutics has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500.

Does the MarketBeat Community believe in IMUX or RNAC?

Immunic received 76 more outperform votes than Cartesian Therapeutics when rated by MarketBeat users. However, 95.12% of users gave Cartesian Therapeutics an outperform vote while only 66.09% of users gave Immunic an outperform vote.

Company	Underperform	Outperform
Immunic	Outperform Votes 115 66.09%	Underperform Votes 59 33.91%
Cartesian Therapeutics	Outperform Votes 39 95.12%	Underperform Votes 2 4.88%

Does the media favor IMUX or RNAC?

In the previous week, Immunic had 11 more articles in the media than Cartesian Therapeutics. MarketBeat recorded 14 mentions for Immunic and 3 mentions for Cartesian Therapeutics. Cartesian Therapeutics' average media sentiment score of 0.94 beat Immunic's score of 0.80 indicating that Cartesian Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Immunic	5 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Cartesian Therapeutics	2 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Is IMUX or RNAC more profitable?

Immunic has a net margin of 0.00% compared to Cartesian Therapeutics' net margin of -510.72%. Cartesian Therapeutics' return on equity of 0.00% beat Immunic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Immunic	N/A	-169.55%	-118.96%
Cartesian Therapeutics	-510.72%	N/A	-6.03%

Do institutionals and insiders hold more shares of IMUX or RNAC?

51.8% of Immunic shares are held by institutional investors. Comparatively, 86.9% of Cartesian Therapeutics shares are held by institutional investors. 3.0% of Immunic shares are held by company insiders. Comparatively, 60.3% of Cartesian Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Do analysts prefer IMUX or RNAC?

Immunic presently has a consensus price target of $11.60, indicating a potential upside of 1,210.29%. Cartesian Therapeutics has a consensus price target of $43.00, indicating a potential upside of 299.26%. Given Immunic's stronger consensus rating and higher probable upside, equities analysts plainly believe Immunic is more favorable than Cartesian Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Immunic	0 Sell rating(s)	0 Hold rating(s)	6 Buy rating(s)	2 Strong Buy rating(s)	3.25
Cartesian Therapeutics	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Which has better earnings & valuation, IMUX or RNAC?

Immunic has higher earnings, but lower revenue than Cartesian Therapeutics. Immunic is trading at a lower price-to-earnings ratio than Cartesian Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Immunic	N/A	N/A	-$93.61M	-$1.23	-0.72
Cartesian Therapeutics	$34.17M	8.18	-$219.71M	-$52.83	-0.20

Summary

Immunic beats Cartesian Therapeutics on 10 of the 18 factors compared between the two stocks.